Skip to main content
×
Home

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

  • S. Leucht (a1), W. Kissling (a1) and J. M. Davis (a2)
Abstract

The initial enthusiasm about the second-generation or atypical antipsychotic drugs soon changed into criticism and debate, culminating in the controversial CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness), CUtLASS (Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study) and EUFEST (European First-Episode Schizophrenia Trial) effectiveness trials. This review summarizes the results of three recent meta-analyses that compared second-generation antipsychotics (SGAs) with placebo, with conventional antipsychotics, and with SGAs head-to-head. We compare the meta-analyses with previous reviews and put them in the perspective of CATIE, CUtLASS and EUFEST. The data show that the SGAs are not a homogeneous group and that this confusing classification should be abandoned. We find that, overall, the data are consistent but experts interpret the same results differently. The debate seems to be driven more by values than by data; some place an emphasis on cost, others focus on extrapyramidal side-effects (EPS), weight gain, or efficacy. In our opinion, the SGAs are not the breakthrough that industry would like to maintain. They have different properties, so a clinician may individualize a treatment plan to a given patient's problems, a decision that should be shared with the patient. However, these drugs are important contributions to treatment, and most psychiatrists, let alone patients, would probably not want to do without them.

Copyright
Corresponding author
*Address for correspondence: S. Leucht, M.D., Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Ismaningerstr. 22, 81675 München, Germany. (Email: Stefan.Leucht@Lrz.tu-muenchen.de)
References
Hide All
Adams CE, Coutinho E, Davis JM, Duggan L, Li C, Leucht S, Tharyan P, Cochrane Schizophrenia Group (2008). In The Cochrane Library. John Wiley & Sons Ltd: Chichester, UK.
Davis JM, Chen N (2001). The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. Journal of Clinical Psychiatry 62, 757771.
Davis JM, Chen N (2004). Dose–response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology 24, 192208.
Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 553564.
Davis JM, Chen N, Glick ID (2008). Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect. Neuropsychopharmacology 33, 971975.
Findling RA, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH (2008). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. American Journal of Psychiatry 165, 14321441.
Geddes J, Freemantle N, Harrison P, Bebbington P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321, 13711376.
Goode E (2003). Leading drugs for psychosis come under new scrutiny. The New York Times, 20 May 2003.
Hamann J, Leucht S, Kissling W (2003). Shared decision making in psychiatry. Acta Psychiatrica Scandinavica 107, 403409.
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006). Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 163, 185194.
Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I (1993). Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica 88, 395402.
Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63, 10791086.
Joy CB, Adams CE, Laurie S (2007). Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. Issue No. 4. Article No. CD003082.
Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 10851097.
Kane JM, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789796.
Kasper S, Winkler D (2006). Addressing the limitations of the CATIE study. World Journal of Biological Psychiatry 7, 126127.
Kemmler G, Hummer M, Widschwendter C, Fleischhacker W (2005). Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Archives of General Psychiatry 62, 13051312.
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, McIntyre JS, Charles SC, Altshuler K, Cook I, Cross CD, Mellman L, Moench LA, Norquist G, Twemlow SW, Woods S, Yager J, Gray SH, Askland K, Pandya R, Prasad K, Johnston R, Nininger J, Peele R, Anzia DJ, Benson RS, Lurie L, Walker RD, Kunkle R, Simpson A, Fochtmann LJ, Hart C, Regier D (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161, 156.
Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2008 a). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry. Published online: 8 January 2008. doi:10.1038/sj.mp.4002136.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009 a). Second-generation versus first-generation antipsychotics for schizophrenia: a meta-analysis. Lancet 373, 3141.
Leucht S, Engel RR, Bauml J, Davis JM (2007). Is the superior efficacy of new generation antipsychotics an artifact of LOCF? Schizophrenia Bulletin 33, 183191.
Leucht S, Heres S, Hamann J, Kane JM (2008 b). Methodological issues in current antipsychotic drug trials. Schizophrenia Bulletin 34, 275285.
Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009 b). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166, 152163.
Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32, 715723.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 12091223.
Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry 58, 538546.
Mattes JA (1997). Risperidone: how good is the evidence for efficacy? Schizophrenia Bulletin 23, 155161.
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600610.
Olie JP, Spina E, Murray S, Yang R (2006). Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. International Clinical Psychopharmacology 21, 143151.
Rosenheck R, Cramer J, Xu WC, Thomas J, Henderson W, Frisman L, Fye C, Charney D (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 337, 809815.
Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Journal of the American Medical Association 290, 26932702.
Rosenheck RA (2005). Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatric Services 56, 8592.
Scherk H, Pajonk FG, Leucht S (2007). Second-generation antipsychotics in the treatment of acute mania: a systematic review and meta-analysis of randomized, controlled trials. Archives of General Psychiatry 64, 442455.
Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G (2005). Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. American Journal of Psychiatry 162, 947953.
Simpson GM, Josiassen RC, Stanilla JK, De Leon J, Nair C, Abraham G, Odom WA, Turner RM (1999). Double-blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry 156, 17441750.
Tarnow-Mordi WO, Healy MJ (1999). Distinguishing between ‘no evidence of effect’ and ‘evidence of no effect’ in randomised controlled trials and other comparisons. Archives of Disease in Childhood 80, 210211.
Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, Adan F, Ainslie G, Allan E, Atri P, Baker R, Beitman B, Brown G, Canive J, Carman J, Dott S, Edwards J, Fenton W, Freidli J, Funderburg L, Ereshefsky L, Gladson M, Hamilton J, Haque S, Hartford J, Horne R, Houck C, Jampala C, Labelle A, Larson G, Liesem M, Liskow B, Makela E, Moore N, Morphy M, Posever T, Risch S, Rotrosen J, Sheehan D, Silverstone P, Swann A, Tapp A, Thomas M, Volavka J, Vora S (1997). Controlled, dose response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry 154, 782791.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 4
Total number of PDF views: 76 *
Loading metrics...

Abstract views

Total abstract views: 381 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 23rd November 2017. This data will be updated every 24 hours.